Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children.
Hematopoietic stem cell transplantation (HCT) may offer the only curative therapy for certain life-threatening immune deficiency disorders. Conventional HCT poses a risk to patients for severe morbidity, mortality, and late sequelae resulting from myeloablative preparative regimens. This review summarizes the development of nonmyeloablative regimens that have the potential to reduce both short- and long-term risks of HCT. Results of NM-HCT in a small number of patients indicate that this procedure may play an important role in treatment of life-threatening immune deficiencies.
Woolfrey
Ann E
AE
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, USA.
Pulsipher
Michael A
MA
Storb
Rainer
R
D002648:Child; D006086:Graft vs Host Disease; D006402:Hematologic Diseases / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use
D007166:Immunosuppressive Agents